Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04148391 · ClinicalTrials.gov registry record · Phase 2

NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)

A Phase 2 study of Parkinson Disease and Mild Cognitive Impairment, sponsored by Aptinyx.

Active
Registry status
Phase 2
Development phase
99
Enrollment target
20
Study locations

NCT04148391 is a Phase 2 study of Parkinson Disease and Mild Cognitive Impairment that is active but no longer recruiting, run by Aptinyx. The registered enrollment target is 99 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (98% lower). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04148391, a Phase 2 study of Parkinson Disease and Mild Cognitive Impairment, is active but no longer recruiting, sponsored by Aptinyx.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
99 participants
Enrollment target
20
Study locations

Study Summary

A Study to Evaluate NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Associated With Parkinson's Disease or Prodromal or Manifest Lewy Body Dementia

Conditions Studied

Parkinson Disease Mild Cognitive Impairment Lewy Body Disease Mild Dementia

Interventions

  • DRUG Placebo Oral Capsule
  • DRUG NYX-458

Study Locations (20)

Florida

  • Aptinyx Clinical Site - Boca Raton
  • Aptinyx Clinical Site - Bradenton
  • Aptinyx Clinical Site - Miami
  • Aptinyx Clinical Site - Miami
  • Aptinyx Clinical Site - Miami
  • Aptinyx Clinical Site - Miami
  • Aptinyx Clinical Site - Miami Lakes
  • Aptinyx Clinical Site - Orlando
  • Aptinyx Clinical Site - Port Charlotte
  • Aptinyx Clinical Site - Port Orange
  • Aptinyx Clinical Site - Sunrise

California

  • Aptinyx Clinical Site - Fresno
  • Aptinyx Clinical Site - Simi Valley

Arizona

  • Aptinyx Clinical Site - Scottsdale

Georgia

  • Aptinyx Clinical Site - Decatur

Michigan

  • Aptinyx Clinical Site - Farmington Hills

Minnesota

  • Aptinyx Clinical Site - Golden Valley

New Jersey

  • Aptinyx Clinical Site - Toms River

New York

  • Aptinyx Clinical Site - Poughkeepsie

Trial Details

FieldValue
Enrollment Target 99 participants
Start Date 2019-11-14
Est. Completion 2022-12-30
Phase Phase 2

Sponsor

Aptinyx

8 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04148391

The ClinicalTrials.gov registry entry for NCT04148391 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (98% lower). The listed sponsor is Aptinyx, which has 8 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Parkinson Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo Oral Capsule is the first listed.

NCT04148391 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Florida, California, Arizona.

Frequently Asked Questions

What is clinical trial NCT04148391 about?

NCT04148391 is a clinical study titled "NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)". A Study to Evaluate NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Associated With Parkinson's Disease or Prodromal or Manifest Lewy Body Dementia

What is the current status of trial NCT04148391?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 99 participants. The study started on 2019-11-14. Estimated completion is 2022-12-30.

What conditions does trial NCT04148391 study?

This clinical trial studies the following conditions: Parkinson Disease, Mild Cognitive Impairment, Lewy Body Disease, Mild Dementia.

What interventions are being tested in trial NCT04148391?

The interventions under investigation include: Placebo Oral Capsule (DRUG), NYX-458 (DRUG).

Who is sponsoring clinical trial NCT04148391?

This trial is sponsored by Aptinyx, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04148391 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Georgia, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Parkinson Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Parkinson Disease

All registered trials for this condition

Mild Cognitive Impairment

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.